What is Vivos Therapeutics Inc's earnings per share (EPS)?

Vivos Therapeutics Inc (VVOS) reported diluted earnings per share of $-2.07 for fiscal year 2025. This represents a 6.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Vivos Therapeutics Inc Financials

VVOS

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Vivos Therapeutics Inc (VVOS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VVOS FY2025 2026-05-20

Revenue recovery has not created a self-funding model; cash burn and near-term liabilities still expand faster than internal cash.

Across the last three valid years, gross margin stayed near 60.0% even as revenue climbed to $17.4M, yet operating cash flow never approached break-even. With SG&A back up to $27.7M and financing inflows of $18.6M in FY2025, added sales are still being absorbed by overhead rather than reducing dependence on outside capital.

FY2024's balance-sheet repair proved temporary: the current ratio fell from 1.5x to 0.2x, turning liquidity into the immediate constraint rather than growth. That pressure is not mainly a term-debt issue; long-term debt was only $469K while current liabilities reached $18.1M.

Cash burn largely mirrors the income statement, which means losses are economically real rather than accounting noise; FY2025 operating cash outflow was $15.3M against net loss of $21.2M. Even the heavier reinvestment in FY2025 was secondary, with capital spending of $2.3M versus free cash flow of -$17.6M, so operating structure matters more than asset intensity.

Financial Health Signals

Financial Health Score 24/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Vivos Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-9.42

Vivos Therapeutics Inc scores -9.42, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($5.7M) relative to total liabilities ($26.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Weak

3/9

Vivos Therapeutics Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.72x

For every $1 of reported earnings, Vivos Therapeutics Inc generates $0.72 in operating cash flow (-$15.3M OCF vs -$21.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-14.2x

Vivos Therapeutics Inc earns $-14.2 in operating income for every $1 of interest expense (-$19.9M vs $1.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$17.4M

YoY+16.0%

5Y CAGR+5.9%

Vivos Therapeutics Inc generated $17.4M in revenue in fiscal year 2025. This represents an increase of 16.0% from the prior year.

EBITDA

-$18.6M

YoY-75.5%

Vivos Therapeutics Inc's EBITDA was -$18.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 75.5% from the prior year.

Net Income

-$21.2M

YoY-90.1%

Vivos Therapeutics Inc reported -$21.2M in net income in fiscal year 2025. This represents a decrease of 90.1% from the prior year.

EPS (Diluted)

$-2.07

YoY+6.8%

Vivos Therapeutics Inc earned $-2.07 per diluted share (EPS) in fiscal year 2025. This represents an increase of 6.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$17.6M

YoY-32.8%

Vivos Therapeutics Inc generated -$17.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 32.8% from the prior year.

Cash & Debt

$2.0M

YoY-67.6%

5Y CAGR-35.5%

Vivos Therapeutics Inc held $2.0M in cash against $469K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+57.7%

Vivos Therapeutics Inc had 9M shares outstanding in fiscal year 2025. This represents an increase of 57.7% from the prior year.

Margins & Returns

Gross Margin

60.4%

YoY+0.4pp

5Y CAGR-19.3pp

Vivos Therapeutics Inc's gross margin was 60.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the prior year.

Operating Margin

-114.1%

YoY-39.7pp

5Y CAGR-21.9pp

Vivos Therapeutics Inc's operating margin was -114.1% in fiscal year 2025, reflecting core business profitability. This is down 39.7 percentage points from the prior year.

Net Margin

-121.4%

YoY-47.3pp

5Y CAGR-29.1pp

Vivos Therapeutics Inc's net profit margin was -121.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 47.3 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$100K

YoY+0.0%

Vivos Therapeutics Inc invested $100K in research and development in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$2.3M

YoY+312.1%

5Y CAGR+81.2%

Vivos Therapeutics Inc invested $2.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 312.1% from the prior year.

VVOS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$17.4M+16.0%	$15.0M+8.9%	$13.8M-13.9%	$16.0M-5.1%	$16.9M+29.2%	$13.1M
Cost of Revenue	$6.9M+14.8%	$6.0M+2906.0%	$200K0.0%	$200K-50.0%	$400K+300.0%	$100K
Gross Profit	$10.5M+16.9%	$9.0M+9.0%	$8.3M-17.4%	$10.0M-20.5%	$12.6M+21.0%	$10.4M
R&D Expenses	$100K0.0%	$100K0.0%	$100K-50.0%	$200K0.0%	$200K	N/A
SG&A Expenses	$27.7M+55.1%	$17.9M-20.5%	$22.5M-22.6%	$29.0M+12.6%	$25.8M+60.3%	$16.1M
Operating Income	-$19.9M-78.1%	-$11.2M+35.4%	-$17.3M+30.9%	-$25.0M-22.8%	-$20.4M-69.3%	-$12.0M
Interest Expense	$1.4M	N/A	N/A	N/A	$14K-85.4%	$96K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$21.2M-90.1%	-$11.1M+18.0%	-$13.6M+43.0%	-$23.8M-17.5%	-$20.3M-68.3%	-$12.1M
EPS (Diluted)	$-2.07+6.8%	$-2.22	$-11.14	$-25.90	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$5.1M+34.4%	$3.8M-43.6%	$6.8M+77.6%	$3.8M+26.7%	$3.0M-18.4%	$3.7M-4.2%	$3.9M-4.8%	$4.1M
Cost of Revenue	$2.1M+148.4%	$838K-70.6%	$2.8M+66.4%	$1.7M+13.5%	$1.5M-49.5%	$3.0M+95.5%	$1.5M+8.8%	$1.4M
Gross Profit	$3.1M+2.4%	$3.0M-24.2%	$3.9M+86.6%	$2.1M+39.8%	$1.5M-28.0%	$2.1M-10.2%	$2.3M-12.0%	$2.7M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$9.0M+5.0%	$8.5M+8.3%	$7.9M+23.0%	$6.4M+31.0%	$4.9M+12.5%	$4.3M-3.1%	$4.5M+8.9%	$4.1M
Operating Income	-$6.6M-3.7%	-$6.4M-34.7%	-$4.7M+2.7%	-$4.9M-24.2%	-$3.9M-39.7%	-$2.8M-6.0%	-$2.6M-36.6%	-$1.9M
Interest Expense	$1.1M	N/A	$500K	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$7.7M-11.4%	-$6.9M-27.6%	-$5.4M-7.7%	-$5.0M-29.7%	-$3.9M-36.7%	-$2.8M-8.1%	-$2.6M-35.5%	-$1.9M
EPS (Diluted)	$-0.52	N/A	$-0.49+10.9%	$-0.55-22.2%	$-0.45	N/A	$-0.40+33.3%	$-0.60

VVOS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$25.2M+64.6%	$15.3M+42.4%	$10.7M-21.8%	$13.7M-59.3%	$33.7M+33.0%	$25.3M
Current Assets	$4.4M-41.3%	$7.5M+203.7%	$2.5M-54.6%	$5.4M-80.1%	$27.3M+34.0%	$20.4M
Cash & Equivalents	$2.0M-67.6%	$6.3M+281.0%	$1.6M-53.3%	$3.5M-85.4%	$24.0M+32.0%	$18.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.6M+267.7%	$430K+112.9%	$202K-55.8%	$457K-62.0%	$1.2M-15.9%	$1.4M
Goodwill	$8.6M+201.5%	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M+6.4%	$2.7M
Total Liabilities	$26.7M+264.3%	$7.3M-29.0%	$10.3M+15.7%	$8.9M+9.4%	$8.2M-3.1%	$8.4M
Current Liabilities	$18.1M+263.1%	$5.0M-31.7%	$7.3M+7.0%	$6.8M-9.3%	$7.5M-4.2%	$7.8M
Long-Term Debt	$469K-60.9%	$1.2M0.0%	$1.2M	N/A	$1.3M+199.1%	$423K
Total Equity	-$1.5M-118.7%	$8.0M+1835.3%	$411K-91.4%	$4.8M-81.2%	$25.5M+51.0%	$16.9M
Retained Earnings	-$125.4M-20.3%	-$104.2M-12.0%	-$93.1M-17.1%	-$79.5M-42.9%	-$55.6M-57.4%	-$35.3M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$25.0M-0.4%	$25.2M-1.9%	$25.6M-1.5%	$26.0M+130.7%	$11.3M-26.2%	$15.3M-0.4%	$15.3M-3.1%	$15.8M
Current Assets	$4.8M+9.9%	$4.4M-24.2%	$5.8M-14.0%	$6.7M+86.6%	$3.6M-51.7%	$7.5M+1.0%	$7.4M-5.8%	$7.9M
Cash & Equivalents	$2.1M+4.0%	$2.0M-34.3%	$3.1M-29.9%	$4.4M+88.0%	$2.3M-62.6%	$6.3M-0.8%	$6.3M-8.6%	$6.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.8M+11.9%	$1.6M-25.9%	$2.1M+30.7%	$1.6M+127.4%	$718K+67.0%	$430K-5.3%	$454K+14.9%	$395K
Goodwill	$8.6M0.0%	$8.6M+1.4%	$8.4M0.0%	$8.4M+197.2%	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M
Total Liabilities	$26.3M-1.5%	$26.7M+15.5%	$23.1M+7.7%	$21.4M+212.0%	$6.9M-6.2%	$7.3M-4.6%	$7.7M-19.1%	$9.5M
Current Liabilities	$17.9M-0.8%	$18.1M+143.1%	$7.4M+15.7%	$6.4M+36.7%	$4.7M-5.6%	$5.0M-2.9%	$5.1M-22.8%	$6.6M
Long-Term Debt	$418K-10.9%	$469K-94.4%	$8.4M+8.0%	$7.8M	N/A	$1.2M0.0%	$1.2M0.0%	$1.2M
Total Equity	-$1.1M+23.6%	-$1.5M-158.8%	$2.5M-44.8%	$4.6M+4.0%	$4.4M-44.6%	$8.0M+3.8%	$7.7M+20.8%	$6.3M
Retained Earnings	-$133.0M-6.1%	-$125.4M-5.8%	-$118.5M-4.8%	-$113.1M-4.6%	-$108.1M-3.7%	-$104.2M-2.8%	-$101.4M-2.6%	-$98.7M

VVOS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$15.3M-20.3%	-$12.7M-6.2%	-$11.9M+39.0%	-$19.6M-24.5%	-$15.7M-177.0%	-$5.7M
Capital Expenditures	$2.3M+312.1%	$568K-29.3%	$803K-13.1%	$924K-61.4%	$2.4M+1896.7%	$120K
Free Cash Flow	-$17.6M-32.8%	-$13.3M-4.0%	-$12.7M+37.8%	-$20.5M-13.1%	-$18.1M-212.6%	-$5.8M
Investing Cash Flow	-$7.5M-1225.0%	-$568K+33.4%	-$853K+7.7%	-$924K+64.6%	-$2.6M-2073.3%	-$120K
Financing Cash Flow	$18.6M+3.8%	$17.9M+63.7%	$10.9M	N/A	$24.2M+2.7%	$23.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$6.0M-57.7%	-$3.8M+8.4%	-$4.2M-19.1%	-$3.5M+8.0%	-$3.8M-29.1%	-$2.9M+29.8%	-$4.2M-37.4%	-$3.0M
Capital Expenditures	$18K-98.8%	$1.5M+1944.6%	-$83K-110.8%	$771K+532.0%	$122K-26.1%	$165K-14.1%	$192K+220.0%	$60K
Free Cash Flow	-$6.0M-12.8%	-$5.3M-25.9%	-$4.2M+0.5%	-$4.3M-8.9%	-$3.9M-26.2%	-$3.1M+29.1%	-$4.4M-40.9%	-$3.1M
Investing Cash Flow	-$18K+98.9%	-$1.6M-2004.8%	$83K+101.4%	-$5.9M-4741.0%	-$122K+26.1%	-$165K+14.1%	-$192K-220.0%	-$60K
Financing Cash Flow	$6.1M+40.9%	$4.3M+56.9%	$2.8M	N/A	N/A	$3.1M-19.4%	$3.8M-48.8%	$7.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VVOS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	60.4%+0.4pp	60.0%+0.1pp	59.9%-2.6pp	62.5%-12.1pp	74.7%-5.0pp	79.7%
Operating Margin	-114.1%-39.7pp	-74.3%+51.0pp	-125.3%+30.9pp	-156.2%-35.5pp	-120.7%-28.6pp	-92.2%
Net Margin	-121.4%-47.3pp	-74.1%+24.3pp	-98.4%+50.4pp	-148.8%-28.7pp	-120.2%-27.9pp	-92.3%
Return on Equity	N/A	-140.0%+3164.9pp	-3304.9%-2808.2pp	-496.7%-417.2pp	-79.4%-8.2pp	-71.3%
Return on Assets	-84.2%-11.3pp	-72.9%+53.7pp	-126.6%+47.2pp	-173.8%-113.6pp	-60.2%-12.6pp	-47.6%
Current Ratio	0.24-1.3	1.50+1.2	0.34-0.5	0.80-2.8	3.64+1.0	2.60
Debt-to-Equity	-0.31-0.5	0.15-2.8	2.92+1.1	1.86+1.8	0.05+0.0	0.03
FCF Margin	-100.9%-12.7pp	-88.2%+4.2pp	-92.4%+35.6pp	-128.0%-20.6pp	-107.4%-63.0pp	-44.4%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	59.5%-18.6pp	78.1%+20.1pp	58.0%+2.8pp	55.2%+5.2pp	50.0%-6.7pp	56.7%-3.8pp	60.5%-4.9pp	65.4%
Operating Margin	-128.7%+38.1pp	-166.8%-97.0pp	-69.8%+57.6pp	-127.4%+2.5pp	-129.9%-54.1pp	-75.8%-7.3pp	-68.5%-20.8pp	-47.8%
Net Margin	-149.4%+30.8pp	-180.3%-100.6pp	-79.6%+51.6pp	-131.2%-3.1pp	-128.1%-51.7pp	-76.4%-8.7pp	-67.8%-20.2pp	-47.6%
Return on Equity	N/A	N/A	-213.3%-103.9pp	-109.4%-21.7pp	-87.7%-52.1pp	-35.5%-1.4pp	-34.1%-3.7pp	-30.4%
Return on Assets	-30.7%-3.3pp	-27.4%-6.3pp	-21.1%-1.8pp	-19.3%+15.0pp	-34.3%-15.8pp	-18.5%-1.4pp	-17.1%-4.9pp	-12.2%
Current Ratio	0.27+0.0	0.24-0.5	0.78-0.3	1.05+0.3	0.77-0.7	1.50+0.1	1.44+0.3	1.18
Debt-to-Equity	-0.37-0.1	-0.31-3.6	3.31+1.6	1.69+0.1	1.56+1.4	0.150.0	0.16-0.0	0.19
FCF Margin	-117.3%+22.5pp	-139.7%-77.1pp	-62.6%+49.1pp	-111.7%+18.3pp	-129.9%-45.9pp	-84.0%+29.5pp	-113.5%-36.8pp	-76.7%

Note: Shareholder equity is negative (-$1.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.24), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

$11.8M

$39.9M

$58.5M

$40.6M

$16.6M

Frequently Asked Questions

What is Vivos Therapeutics Inc's annual revenue?

Vivos Therapeutics Inc (VVOS) reported $17.4M in total revenue for fiscal year 2025. This represents a 16.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Vivos Therapeutics Inc's revenue growing?

Vivos Therapeutics Inc (VVOS) revenue grew by 16% year-over-year, from $15.0M to $17.4M in fiscal year 2025.

Is Vivos Therapeutics Inc profitable?

No, Vivos Therapeutics Inc (VVOS) reported a net income of -$21.2M in fiscal year 2025, with a net profit margin of -121.4%.

What is Vivos Therapeutics Inc's EBITDA?

Vivos Therapeutics Inc (VVOS) had EBITDA of -$18.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Vivos Therapeutics Inc have?

As of fiscal year 2025, Vivos Therapeutics Inc (VVOS) had $2.0M in cash and equivalents against $469K in long-term debt.

What is Vivos Therapeutics Inc's gross margin?

Vivos Therapeutics Inc (VVOS) had a gross margin of 60.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Vivos Therapeutics Inc's operating margin?

Vivos Therapeutics Inc (VVOS) had an operating margin of -114.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Vivos Therapeutics Inc's net profit margin?

Vivos Therapeutics Inc (VVOS) had a net profit margin of -121.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Vivos Therapeutics Inc's free cash flow?

Vivos Therapeutics Inc (VVOS) generated -$17.6M in free cash flow during fiscal year 2025. This represents a -32.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Vivos Therapeutics Inc's operating cash flow?

Vivos Therapeutics Inc (VVOS) generated -$15.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Vivos Therapeutics Inc's total assets?

Vivos Therapeutics Inc (VVOS) had $25.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Vivos Therapeutics Inc's capital expenditures?

Vivos Therapeutics Inc (VVOS) invested $2.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Vivos Therapeutics Inc spend on research and development?

Vivos Therapeutics Inc (VVOS) invested $100K in research and development during fiscal year 2025.

How many shares does Vivos Therapeutics Inc have outstanding?

Vivos Therapeutics Inc (VVOS) had 9M shares outstanding as of fiscal year 2025.

What is Vivos Therapeutics Inc's current ratio?

Vivos Therapeutics Inc (VVOS) had a current ratio of 0.24 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Vivos Therapeutics Inc's debt-to-equity ratio?

Vivos Therapeutics Inc (VVOS) had a debt-to-equity ratio of -0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Vivos Therapeutics Inc's return on assets (ROA)?

Vivos Therapeutics Inc (VVOS) had a return on assets of -84.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Vivos Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Vivos Therapeutics Inc (VVOS) had $2.0M in cash against an annual operating cash burn of $15.3M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Vivos Therapeutics Inc's debt-to-equity ratio negative or unusual?

Vivos Therapeutics Inc (VVOS) has negative shareholder equity of -$1.5M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Vivos Therapeutics Inc's Altman Z-Score?

Vivos Therapeutics Inc (VVOS) has an Altman Z-Score of -9.42, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Vivos Therapeutics Inc's Piotroski F-Score?

Vivos Therapeutics Inc (VVOS) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Vivos Therapeutics Inc's earnings high quality?

Vivos Therapeutics Inc (VVOS) has an earnings quality ratio of 0.72x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Vivos Therapeutics Inc cover its interest payments?

Vivos Therapeutics Inc (VVOS) has an interest coverage ratio of -14.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Vivos Therapeutics Inc?

Vivos Therapeutics Inc (VVOS) scores 24 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.